ClinicalTrials.gg
CompletedNCT06092931Updated Oct 19, 2026Results posted

A Drug-Drug Interaction Study Evaluating the Perpetrator Potential of DC-806 on Cocktails of CYP450 Enzyme and Transporter Substrates in Healthy Participants

A Phase 1 interventional study of DC-806 and Midazolam in Healthy Participants, sponsored by DICE Therapeutics, Inc., a wholly owned subsidiary of Eli Lilly and Company. Completed at 1 site in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-19.

Sponsored by DICE Therapeutics, Inc., a wholly owned subsidiary of Eli Lilly and Company (part of Eli Lilly and Company) · Phase 1, Interventional, and Basic science

Updated Oct 19, 2026Results postedStudy documents posted+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
28
Allocation
Non-randomized
Ages
18 Years to 55 Years
Sex
All
01

Study summary

The main objective of this study is to assess the effect of DC-806 on the pharmacokinetics (PK) of cytochrome 3A4 (CYP3A4) substrate, midazolam and its active metabolite, 1-hydroxymidazolam, cytochrome 2C8 (CYP2C8) substrate repaglinide, P-glycoprotein (P-gp) transporter substrate digoxin, and breast cancer resistant protein (BCRP)/ organic anion transporter protein-1B1 (OATP1B1) transporter substrate rosuvastatin in healthy participants.

02

Conditions studied

  • Healthy Participants

Keywords

  • DC-806
  • Drug-drug interaction
  • Midazolam
  • Repaglinide
  • Digoxin
  • Rosuvastatin
03

In context

Lead sponsor

DICE Therapeutics, Inc., a wholly owned subsidiary of Eli Lilly and Company is the lead sponsor of 10 studies on the registry; none are open to participants now.

Of its 10 completed or terminated interventional studies of FDA-regulated products, 4 (40%) have results posted.

First submitted after DICE Therapeutics, Inc. became part of Eli Lilly and Company.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Sex: male or female; females must be of nonchildbearing potential, or .
  2. Age: 18 to 55 years, inclusive, at screening.
  3. : 18.0 to 32.0 kg/m\^2, inclusive, at screening.
  4. Weight: ≥50 kg at screening.
  5. Status: healthy participants.
  6. At screening, females must be of nonchildbearing potential (defined as at least 12 consecutive months with no menses prior to screening, a serum follicle-stimulating hormone test to confirm postmenopausal status, or being surgically sterilized); nonpregnancy will be confirmed for all females by a serum pregnancy test conducted at screening, and by a urine pregnancy test at admission and at follow-up.
  7. Male participants, if not permanently surgically sterilized, must inform all sexual partners of their participation in a research study and agree to use a highly effective method of and not donate sperm from admission to the clinical site until 30 days after the last study drug administration.
  8. All prescribed medication must have been stopped at least 14 days prior to admission to the clinical site.
  9. All over-the-counter medication, vitamin preparations and other food supplements, or herbal medications (e.g., St. John's wort) must have been stopped at least 7 days (or 5 half-lives for certain medications, whichever is longer) prior to admission to the clinical site. Occasional use of acetaminophen/paracetamol (e.g., up to 2 grams per day) is permitted during this period and throughout the study.
  10. Ability and willingness to abstain from alcohol-, caffeine-, and methylxanthine- containing beverages or food (e.g., coffee, tea, cola, chocolate, energy drinks) from 48 hours (2 days) prior to admission to the clinical site and during confinement at the clinical site.
  11. Willingness to abstain from any strenuous physical exercise from 96 hours (4 days) prior to admission and during confinement at the clinical site.
  12. Good physical and mental health on the basis of medical history, physical examination, clinical laboratory assessments, 12-lead , and vital signs, as judged by the Investigator.
  13. Willing and able to sign the form.

Exclusion criteria

Exclusion Criteria:

  1. Employee of Contract Research Organization or the Sponsor.
  2. History of relevant drug and/or food allergies, in the opinion of the Investigator.
  3. Females who are currently breastfeeding.
  4. Smoking more than 5 cigarettes, 1 cigar, or 1 pipe daily within 3 months prior to screening.
  5. Unwilling or unable to abstain from tobacco products within the 48 hours (2 days) prior to admission and during confinement in the clinical site.
  6. History of alcohol abuse or drug addiction (including soft drugs like cannabis products) within 1 year prior to screening.
  7. Positive drug and/or alcohol screen (opiates, methadone, cocaine, amphetamines [including ecstasy], cannabinoids, barbiturates, benzodiazepines, tricyclic antidepressants, and alcohol) at screening or admission to the clinical site.
  8. History within the previous 12 months of alcohol consumption exceeding 2 standard drinks per day on average. Alcohol consumption will be prohibited 48 hours prior to admission to the clinical site and during confinement at the clinical site.
  9. Positive screen for surface antigen, virus antibodies, or 1 and 2 antibodies.
  10. Consumption of any nutrients known to modulate CYP450 enzymes activity (e.g., grapefruit or grapefruit juice, pomelo juice, star fruit, or Seville [blood] orange products) within 14 days prior to the first administration of study drug and during the study (including /clinic furlough until after discharge in the last study period).
  11. Participation in a drug study within 30 days prior to study drug administration in the current study. Participation in 4 or more other drug studies in the 12 months prior to study drug administration in the current study.
  12. History of donation of more than 450 mL of blood within 60 days prior to dosing in the clinical site or planned donation before 30 days has elapsed since intake of study drug.
  13. Plasma or donation within 7 days of dosing and through follow-up.
  14. Significant and/or acute illness within 5 days prior to study drug administration that may impact safety assessments, in the opinion of the Investigator.
  15. Unsuitable veins for infusion or blood sampling as determined by the Investigator or study staff.
  16. Any other condition or prior therapy that, in the Investigator's opinion, would confound or interfere with the evaluation of safety, tolerability, or PK of the study drug, interfere with study compliance, or preclude .
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
28 participants (actual)

Study arms

  • Experimental
    Cohort 1: DC-806 / Midazolam (CYP3A4 Substrate) + Repaglinide (CYP2C8 Substrate)

    * Participants were administered a single oral dose of the 2-probe CYP substrate cocktail consisting of 2 milligram (mg) midazolam and 0.5 mg repaglinide under fasted conditions in the morning on Day 1. * From Days 4 through 8, participants received oral doses of 800 mg DC-806 twice daily. A single oral dose of 2-probe CYP substrate cocktail consisting of 2 mg midazolam and 0.5 mg repaglinide was co-administered under fasted conditions 1.5 hours after DC-806 dosing in the morning of Day 7.

    Drug: DC-806 · Drug: Midazolam · Drug: Repaglinide

  • Experimental
    Cohort 2: DC-806 / Digoxin (P-gp Substrate) + Rosuvastatin (BCRP/OATP1B1 Substrate)

    * Participants were administered a single oral dose of the 2-probe transporter substrate cocktail consisting of 0.25 mg digoxin and 5 mg rosuvastatin under fasted conditions in the morning on Day 1. * From Days 5 through 9, participants received oral doses of 800 mg of DC-806 twice daily. A single oral dose of the 2-probe transporter substrate cocktail consisting of 0.25 mg digoxin and 5 mg rosuvastatin was co-administered under fasted conditions 1.5 hours after DC-806 dosing in the morning of Day 8.

    Drug: DC-806 · Drug: Digoxin · Drug: Rosuvastatin

Interventions

  • DrugDC-806

    Oral tablets

  • DrugMidazolam

    Oral syrup

  • Oral tablets

  • DrugDigoxin

    Oral tablets

  • DrugRosuvastatin

    Oral tablets

06

What researchers measure

Primary outcomes

  1. Cohort 1: Maximum Observed Plasma Concentration (Cmax) of Midazolam

    The timepoints mentioned in the timeframe were relative to the administration of the 2-probe CYP substrate cocktail.

    Time frame: Predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48 hours postdose on Days 1 and 7

  2. Cohort 1: Area Under the Plasma Concentration-time Curve (AUC) From Time Zero to Time t, Where t is the Last Point With Concentrations Above the Lower Limit of Quantification (AUC0-t) of Midazolam

    Cohort 1: AUC0-t of Midazolam. The timepoints mentioned in the timeframe were relative to the administration of the 2-probe CYP substrate cocktail.

    Time frame: Predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48 hours postdose on Days 1 and 7

  3. Cohort 1: AUC From Time 0 to Infinity (AUC0-inf) of Midazolam

    The timepoints mentioned in the timeframe were relative to the administration of the 2-probe CYP substrate cocktail.

    Time frame: Predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48 hours postdose on Days 1 and 7

  4. Cohort 1: Cmax of 1-hydroxymidazolam

    Cohort 1: Cmax of 1-hydroxymidazolam, an active metabolite of midazolam. The timepoints mentioned in the timeframe were relative to the administration of the 2-probe CYP substrate cocktail.

    Time frame: Predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48 hours postdose on Days 1 and 7

  5. Cohort 1: AUC0-t of 1-hydroxymidazolam

    Cohort 1: AUC0-t of 1-hydroxymidazolam, an active metabolite of midazolam. The timepoints mentioned in the timeframe were relative to the administration of the 2-probe CYP substrate cocktail.

    Time frame: Predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48 hours postdose on Days 1 and 7

  6. Cohort 1: AUC0-inf of 1-hydroxymidazolam

    Cohort 1: AUC0-inf of 1-hydroxymidazolam, an active metabolite of midazolam. The timepoints mentioned in the timeframe were relative to the administration of the 2-probe CYP substrate cocktail.

    Time frame: Predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48 hours postdose on Days 1 and 7

  7. Cohort 1: Cmax of Repaglinide

    The timepoints mentioned in the timeframe were relative to the administration of the 2-probe CYP substrate cocktail.

    Time frame: Predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24 hours postdose on Days 1 and 7

  8. Cohort 1: AUC0-t of Repaglinide

    The timepoints mentioned in the timeframe were relative to the administration of the 2-probe CYP substrate cocktail.

    Time frame: Predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24 hours postdose on Days 1 and 7

  9. Cohort 1: AUC0-inf of Repaglinide

    The timepoints mentioned in the timeframe were relative to the administration of the 2-probe CYP substrate cocktail.

    Time frame: Predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24 hours postdose on Days 1 and 7

  10. Cohort 2: Cmax of Digoxin

    The timepoints mentioned in the timeframe were relative to the administration of the 2-probe transporter substrate cocktail.

    Time frame: Predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 96 hours postdose on Days 1 and 8

  11. Cohort 2: AUC0-t of Digoxin

    The timepoints mentioned in the timeframe were relative to the administration of the 2-probe transporter substrate cocktail.

    Time frame: Predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 96 hours postdose on Days 1 and 8

  12. Cohort 2: AUC0-inf of Digoxin

    The timepoints mentioned in the timeframe were relative to the administration of the 2-probe transporter substrate cocktail.

    Time frame: Predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 96 hours postdose on Days 1 and 8

  13. Cohort 2: Cmax of Rosuvastatin

    The timepoints mentioned in the timeframe were relative to the administration of the 2-probe transporter substrate cocktail.

    Time frame: Predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 96 hours postdose on Days 1 and 8

  14. Cohort 2: AUC0-t of Rosuvastatin

    The timepoints mentioned in the timeframe were relative to the administration of the 2-probe transporter substrate cocktail.

    Time frame: Predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 96 hours postdose on Days 1 and 8

  15. Cohort 2: AUC0-inf of Rosuvastatin

    The timepoints mentioned in the timeframe were relative to the administration of the 2-probe transporter substrate cocktail.

    Time frame: Predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 96 hours postdose on Days 1 and 8

Secondary outcomes

  1. Cohorts 1 and 2: Number of Participants With Treatment-Emergent Adverse Events (TEAEs)

    A TEAE was defined as any adverse event that began on or after the first dose of study drug or began before the first dose of study drug and worsened on or after the first dose of study drug.

    Time frame: Cohort 1: Day 1 up to Day 16; Cohort 2: Day 1 up to Day 22

07

Results

Posted Oct 19, 2026

Participant flow

Participant flow — Overall Study
MilestoneCohort 1: DC-806 / Midazolam (CYP3A4 Substrate) + Repaglinide (CYP2C8 Substrate)Cohort 2: DC-806 / Digoxin (P-gp Substrate) + Rosuvastatin (BCRP/OATP1B1 Substrate)
Started1414
Safety analysis set1414
Completed1412
Not completed02
Withdrew: Adverse event02

Outcome measures

PrimaryCohort 1: Maximum Observed Plasma Concentration (Cmax) of Midazolam

The timepoints mentioned in the timeframe were relative to the administration of the 2-probe CYP substrate cocktail.

Time frame:
Predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48 hours postdose on Days 1 and 7
Reported as:
Geometric mean · nanograms per milliliter (ng/mL)
Cohort 1: Maximum Observed Plasma Concentration (Cmax) of Midazolam
nanograms per milliliter (ng/mL)Cohort 1: DC-806 / Midazolam (CYP3A4 Substrate) + Repaglinide (CYP2C8 Substrate)
Day 18.27 ± 27.9
Day 724.9 ± 29.4
PrimaryCohort 1: Area Under the Plasma Concentration-time Curve (AUC) From Time Zero to Time t, Where t is the Last Point With Concentrations Above the Lower Limit of Quantification (AUC0-t) of Midazolam

Cohort 1: AUC0-t of Midazolam. The timepoints mentioned in the timeframe were relative to the administration of the 2-probe CYP substrate cocktail.

Time frame:
Predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48 hours postdose on Days 1 and 7
Reported as:
Geometric mean · hour*nanograms per milliliter (h*ng/mL)
Cohort 1: Area Under the Plasma Concentration-time Curve (AUC) From Time Zero to Time t, Where t is the Last Point With Concentrations Above the Lower Limit of Quantification (AUC0-t) of Midazolam
hour*nanograms per milliliter (h*ng/mL)Cohort 1: DC-806 / Midazolam (CYP3A4 Substrate) + Repaglinide (CYP2C8 Substrate)
Day 118.4 ± 27.4
Day 782.6 ± 36.9
PrimaryCohort 1: AUC From Time 0 to Infinity (AUC0-inf) of Midazolam

The timepoints mentioned in the timeframe were relative to the administration of the 2-probe CYP substrate cocktail.

Time frame:
Predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48 hours postdose on Days 1 and 7
Reported as:
Geometric mean · hour*nanograms per milliliter (h*ng/mL)
Cohort 1: AUC From Time 0 to Infinity (AUC0-inf) of Midazolam
hour*nanograms per milliliter (h*ng/mL)Cohort 1: DC-806 / Midazolam (CYP3A4 Substrate) + Repaglinide (CYP2C8 Substrate)
Day 121.4 ± 24.5
Day 797.1 ± 35.8
PrimaryCohort 1: Cmax of 1-hydroxymidazolam

Cohort 1: Cmax of 1-hydroxymidazolam, an active metabolite of midazolam. The timepoints mentioned in the timeframe were relative to the administration of the 2-probe CYP substrate cocktail.

Time frame:
Predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48 hours postdose on Days 1 and 7
Reported as:
Geometric mean · nanograms per milliliter (ng/mL)
Cohort 1: Cmax of 1-hydroxymidazolam
nanograms per milliliter (ng/mL)Cohort 1: DC-806 / Midazolam (CYP3A4 Substrate) + Repaglinide (CYP2C8 Substrate)
Day 12.94 ± 64.5
Day 72.95 ± 37.9
PrimaryCohort 1: AUC0-t of 1-hydroxymidazolam

Cohort 1: AUC0-t of 1-hydroxymidazolam, an active metabolite of midazolam. The timepoints mentioned in the timeframe were relative to the administration of the 2-probe CYP substrate cocktail.

Time frame:
Predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48 hours postdose on Days 1 and 7
Reported as:
Geometric mean · hour*nanograms per milliliter (h*ng/mL)
Cohort 1: AUC0-t of 1-hydroxymidazolam
hour*nanograms per milliliter (h*ng/mL)Cohort 1: DC-806 / Midazolam (CYP3A4 Substrate) + Repaglinide (CYP2C8 Substrate)
Day 15.05 ± 106.6
Day 77.69 ± 102.3
PrimaryCohort 1: AUC0-inf of 1-hydroxymidazolam

Cohort 1: AUC0-inf of 1-hydroxymidazolam, an active metabolite of midazolam. The timepoints mentioned in the timeframe were relative to the administration of the 2-probe CYP substrate cocktail.

Time frame:
Predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48 hours postdose on Days 1 and 7
Reported as:
Geometric mean · hour*nanograms per milliliter (h*ng/mL)
Cohort 1: AUC0-inf of 1-hydroxymidazolam
hour*nanograms per milliliter (h*ng/mL)Cohort 1: DC-806 / Midazolam (CYP3A4 Substrate) + Repaglinide (CYP2C8 Substrate)
Day 113.2 ± 100.7
Day 711.7 ± 5.4
PrimaryCohort 1: Cmax of Repaglinide

The timepoints mentioned in the timeframe were relative to the administration of the 2-probe CYP substrate cocktail.

Time frame:
Predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24 hours postdose on Days 1 and 7
Reported as:
Geometric mean · nanograms per milliliter (ng/mL)
Cohort 1: Cmax of Repaglinide
nanograms per milliliter (ng/mL)Cohort 1: DC-806 / Midazolam (CYP3A4 Substrate) + Repaglinide (CYP2C8 Substrate)
Day 17.68 ± 50.2
Day 714.4 ± 38.8
PrimaryCohort 1: AUC0-t of Repaglinide

The timepoints mentioned in the timeframe were relative to the administration of the 2-probe CYP substrate cocktail.

Time frame:
Predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24 hours postdose on Days 1 and 7
Reported as:
Geometric mean · hour*nanograms per milliliter (h*ng/mL)
Cohort 1: AUC0-t of Repaglinide
hour*nanograms per milliliter (h*ng/mL)Cohort 1: DC-806 / Midazolam (CYP3A4 Substrate) + Repaglinide (CYP2C8 Substrate)
Day 113.3 ± 62.4
Day 728 ± 48.3
PrimaryCohort 1: AUC0-inf of Repaglinide

The timepoints mentioned in the timeframe were relative to the administration of the 2-probe CYP substrate cocktail.

Time frame:
Predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24 hours postdose on Days 1 and 7
Reported as:
Geometric mean · hour*nanograms per milliliter (h*ng/mL)
Cohort 1: AUC0-inf of Repaglinide
hour*nanograms per milliliter (h*ng/mL)Cohort 1: DC-806 / Midazolam (CYP3A4 Substrate) + Repaglinide (CYP2C8 Substrate)
Day 114.7 ± 69.7
Day 723.8 ± 34.5
PrimaryCohort 2: Cmax of Digoxin

The timepoints mentioned in the timeframe were relative to the administration of the 2-probe transporter substrate cocktail.

Time frame:
Predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 96 hours postdose on Days 1 and 8
Reported as:
Geometric mean · nanograms per milliliter (ng/mL)
Cohort 2: Cmax of Digoxin
nanograms per milliliter (ng/mL)Cohort 2: DC-806 / Digoxin (P-gp Substrate) + Rosuvastatin (BCRP/OATP1B1 Substrate)
Day 10.948 ± 25.0
Day 81.39 ± 23.7
PrimaryCohort 2: AUC0-t of Digoxin

The timepoints mentioned in the timeframe were relative to the administration of the 2-probe transporter substrate cocktail.

Time frame:
Predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 96 hours postdose on Days 1 and 8
Reported as:
Geometric mean · hour*nanograms per milliliter (h*ng/mL)
Cohort 2: AUC0-t of Digoxin
hour*nanograms per milliliter (h*ng/mL)Cohort 2: DC-806 / Digoxin (P-gp Substrate) + Rosuvastatin (BCRP/OATP1B1 Substrate)
Day 114.2 ± 24.2
Day 815.4 ± 28.5
PrimaryCohort 2: AUC0-inf of Digoxin

The timepoints mentioned in the timeframe were relative to the administration of the 2-probe transporter substrate cocktail.

Time frame:
Predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 96 hours postdose on Days 1 and 8
Reported as:
Number · hour*nanograms per milliliter (h*ng/mL)
Cohort 2: AUC0-inf of Digoxin
hour*nanograms per milliliter (h*ng/mL)Cohort 2: DC-806 / Digoxin (P-gp Substrate) + Rosuvastatin (BCRP/OATP1B1 Substrate)
Day 114.6
PrimaryCohort 2: Cmax of Rosuvastatin

The timepoints mentioned in the timeframe were relative to the administration of the 2-probe transporter substrate cocktail.

Time frame:
Predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 96 hours postdose on Days 1 and 8
Reported as:
Geometric mean · nanograms per milliliter (ng/mL)
Cohort 2: Cmax of Rosuvastatin
nanograms per milliliter (ng/mL)Cohort 2: DC-806 / Digoxin (P-gp Substrate) + Rosuvastatin (BCRP/OATP1B1 Substrate)
Day 12.85 ± 60
Day 82.62 ± 85.3
PrimaryCohort 2: AUC0-t of Rosuvastatin

The timepoints mentioned in the timeframe were relative to the administration of the 2-probe transporter substrate cocktail.

Time frame:
Predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 96 hours postdose on Days 1 and 8
Reported as:
Geometric mean · hour*nanograms per milliliter (h*ng/mL)
Cohort 2: AUC0-t of Rosuvastatin
hour*nanograms per milliliter (h*ng/mL)Cohort 2: DC-806 / Digoxin (P-gp Substrate) + Rosuvastatin (BCRP/OATP1B1 Substrate)
Day 129.7 ± 64.5
Day 825.4 ± 56.8
PrimaryCohort 2: AUC0-inf of Rosuvastatin

The timepoints mentioned in the timeframe were relative to the administration of the 2-probe transporter substrate cocktail.

Time frame:
Predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 96 hours postdose on Days 1 and 8
Reported as:
Geometric mean · hour*nanograms per milliliter (h*ng/mL)
Cohort 2: AUC0-inf of Rosuvastatin
hour*nanograms per milliliter (h*ng/mL)Cohort 2: DC-806 / Digoxin (P-gp Substrate) + Rosuvastatin (BCRP/OATP1B1 Substrate)
Day 126.7 ± 47.8
Day 823.1 ± 35.8
SecondaryCohorts 1 and 2: Number of Participants With Treatment-Emergent Adverse Events (TEAEs)

A TEAE was defined as any adverse event that began on or after the first dose of study drug or began before the first dose of study drug and worsened on or after the first dose of study drug.

Time frame:
Cohort 1: Day 1 up to Day 16; Cohort 2: Day 1 up to Day 22
Reported as:
Count of participants · Participants
Cohorts 1 and 2: Number of Participants With Treatment-Emergent Adverse Events (TEAEs)
ParticipantsCohort 1: Midazolam + Repaglinide (Days 1 to 3)Cohort 1: DC-806 (Days 4 to 6)Cohort 1: DC-806 + Midazolam + Repaglinide (From Day 7)Cohort 1: Overall [(DC-806 / Midazolam (CYP3A4 Substrate) + Repaglinide (CYP2C8 Substrate)]Cohort 2: Digoxin + Rosuvastatin (Days 1 to 4)Cohort 2: DC-806 (Days 5 to 7)Cohort 2: DC-806 + Digoxin + Rosuvastatin (From Day 8)Cohort 2: Overall [(DC-806 / Digoxin (P-gp Substrate) + Rosuvastatin (BCRP/OATP1B1 Substrate)]
Cohorts 1 and 2: Number of Participants With Treatment-Emergent Adverse Events (TEAEs)02222215

Adverse events

Collected over Cohort 1: Day 1 up to Day 16; Cohort 2: Day 1 up to Day 22.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Cohort 1: Midazolam + Repaglinide (Days 1 to 3)0/14 (0%)0/14 (0%)0/14 (0%)
Cohort 1: DC-806 (Days 4 to 6)0/14 (0%)0/14 (0%)2/14 (14.3%)
Cohort 1: DC-806 + Midazolam + Repaglinide (From Day 7)0/14 (0%)0/14 (0%)2/14 (14.3%)
Cohort 1: Overall [(DC-806 / Midazolam (CYP3A4 Substrate) + Repaglinide (CYP2C8 Substrate)]0/14 (0%)0/14 (0%)2/14 (14.3%)
Cohort 2: Digoxin + Rosuvastatin (Days 1 to 4)0/14 (0%)0/14 (0%)2/14 (14.3%)
Cohort 2: DC-806 (Days 5 to 7)0/13 (0%)0/13 (0%)2/13 (15.4%)
Cohort 2: DC-806 + Digoxin + Rosuvastatin (From Day 8)0/13 (0%)0/13 (0%)1/13 (7.7%)
Cohort 2: Overall [(DC-806 / Digoxin (P-gp Substrate) + Rosuvastatin (BCRP/OATP1B1 Substrate)]0/14 (0%)0/14 (0%)5/14 (35.7%)
Most frequent other events
Most frequent other events
EventCohort 1: Midazolam + Repaglinide (Days 1 to 3)Cohort 1: DC-806 (Days 4 to 6)Cohort 1: DC-806 + Midazolam + Repaglinide (From Day 7)Cohort 1: Overall [(DC-806 / Midazolam (CYP3A4 Substrate) + Repaglinide (CYP2C8 Substrate)]Cohort 2: Digoxin + Rosuvastatin (Days 1 to 4)Cohort 2: DC-806 (Days 5 to 7)Cohort 2: DC-806 + Digoxin + Rosuvastatin (From Day 8)Cohort 2: Overall [(DC-806 / Digoxin (P-gp Substrate) + Rosuvastatin (BCRP/OATP1B1 Substrate)]
DysgeusiaNervous system disorders0/142/140/142/140/142/131/133/14
DizzinessNervous system disorders0/140/142/142/140/140/130/130/14
Upper respiratory tract infectionInfections and infestations0/140/140/140/140/141/131/132/14
DiarrhoeaGastrointestinal disorders0/140/141/141/140/140/130/130/14
NauseaGastrointestinal disorders0/140/141/141/140/140/130/130/14
VomitingGastrointestinal disorders0/140/141/141/140/140/130/130/14
HeadacheNervous system disorders0/140/140/140/141/140/130/131/14
SomnolenceNervous system disorders0/140/140/140/141/140/130/131/14
SinusitisInfections and infestations0/140/140/140/141/140/130/131/14

Baseline characteristics

All enrolled participants.

Age, Continuous
Age, Continuous(years)Cohort 1: DC-806 / Midazolam (CYP3A4 Substrate) + Repaglinide (CYP2C8 Substrate)Cohort 2: DC-806 / Digoxin (P-gp Substrate) + Rosuvastatin (BCRP/OATP1B1 Substrate)Total
Mean31.9 ± 9.4635.8 ± 11.5733.8 ± 10.56
Sex: Female, Male
Sex: Female, Male(Participants)Cohort 1: DC-806 / Midazolam (CYP3A4 Substrate) + Repaglinide (CYP2C8 Substrate)Cohort 2: DC-806 / Digoxin (P-gp Substrate) + Rosuvastatin (BCRP/OATP1B1 Substrate)Total
Female011
Male141327
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Cohort 1: DC-806 / Midazolam (CYP3A4 Substrate) + Repaglinide (CYP2C8 Substrate)Cohort 2: DC-806 / Digoxin (P-gp Substrate) + Rosuvastatin (BCRP/OATP1B1 Substrate)Total
Hispanic or Latino5510
Not Hispanic or Latino9918
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Cohort 1: DC-806 / Midazolam (CYP3A4 Substrate) + Repaglinide (CYP2C8 Substrate)Cohort 2: DC-806 / Digoxin (P-gp Substrate) + Rosuvastatin (BCRP/OATP1B1 Substrate)Total
American Indian or Alaska Native000
Asian000
Native Hawaiian or Other Pacific Islander000
Black or African American022
White131225
More than one race101
Unknown or Not Reported000
Region of Enrollment
Region of Enrollment(Participants)Cohort 1: DC-806 / Midazolam (CYP3A4 Substrate) + Repaglinide (CYP2C8 Substrate)Cohort 2: DC-806 / Digoxin (P-gp Substrate) + Rosuvastatin (BCRP/OATP1B1 Substrate)Total
United States141428
08

Study locations

1 site
  • ICON Phase 1 Clinic
    Salt Lake City, Utah 84124, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Oct 2023 to primary completion in Nov 2023, 1 month.

Results were first posted in Oct 2026, 2 years 10 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 16, 2023
First posted
Oct 23, 2023
StartActual
Oct 16, 2023
Primary completionActual
Nov 28, 2023
CompletionActual
Nov 28, 2023
Results first posted
Oct 19, 2026
Last update
Oct 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Results
Results posted
posted Oct 19, 2026
Interventions
Arm changed Cohort 1: DC-806 + Midazolam (CYP3A4 substrate) + Repaglinide (CYP2C8 substrate)→Cohort 1: DC-806 / Midazolam (CYP3A4 Substrate) + Repaglinide (CYP2C8 Substrate); Cohort 2: DC-806 + Digoxin (P-gp substrate) + Rosuvastatin (BCRP/OATP1B1 substrate)→Cohort 2: DC-806 / Digoxin (P-gp Substrate) + Rosuvastatin (BCRP/OATP1B1 Substrate)
Oct 19, 2026
Primary outcomes
2 edited, 13 time frame changed, 13 description edited
What changed in the outcomes
  • EditedCohort 1: Area Under the Plasma Concentration-time Curve (AUC) upFrom Time Zero to Time t, Where t is the Last Point withWith Concentrations Above the Lower Limit of Quantification (AUC0-t) of MidazolamTime frame: Days 1-3 and Days 7-9 → Predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48 hours postdose on Days 1 and 7
  • EditedCohort 1: AUC fromFrom Time 0 to Infinity (AUC0-inf) of MidazolamTime frame: Days 1-3 and Days 7-9 → Predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48 hours postdose on Days 1 and 7
  • Time frameCohort 1: Maximum Observed Plasma Concentration (Cmax) of MidazolamDay 1 and Day 7 → Predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48 hours postdose on Days 1 and 7
  • Time frameCohort 1: Cmax of 1-hydroxymidazolamDay 1 and Day 7 → Predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48 hours postdose on Days 1 and 7
  • Time frameCohort 1: Cmax of RepaglinideDay 1 and Day 7 → Predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24 hours postdose on Days 1 and 7
  • Time frameCohort 2: Cmax of DigoxinDay 1 and Day 8 → Predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 96 hours postdose on Days 1 and 8
  • Time frameCohort 2: Cmax of RosuvastatinDay 1 and Day 8 → Predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 96 hours postdose on Days 1 and 8
  • Time frameCohort 1: AUC0-t of 1-hydroxymidazolamDays 1-3 and Days 7-9 → Predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48 hours postdose on Days 1 and 7
  • Time frameCohort 1: AUC0-t of RepaglinideDays 1-3 and Days 7-9 → Predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24 hours postdose on Days 1 and 7
  • Time frameCohort 2: AUC0-t of DigoxinDays 1-5 and Days 8-12 → Predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 96 hours postdose on Days 1 and 8
  • Time frameCohort 2: AUC0-t of RosuvastatinDays 1-5 and Days 8-12 → Predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 96 hours postdose on Days 1 and 8
  • Time frameCohort 1: AUC0-inf of 1-hydroxymidazolamDays 1-3 and Days 7-9 → Predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48 hours postdose on Days 1 and 7
  • Time frameCohort 1: AUC0-inf of RepaglinideDays 1-3 and Days 7-9 → Predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24 hours postdose on Days 1 and 7
  • Time frameCohort 2: AUC0-inf of DigoxinDays 1-5 and Days 8-12 → Predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 96 hours postdose on Days 1 and 8
  • Time frameCohort 2: AUC0-inf of RosuvastatinDays 1-5 and Days 8-12 → Predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 96 hours postdose on Days 1 and 8
  • DescriptionCohort 1: AUC0-inf of 1-hydroxymidazolam: how it is measured was reworded
  • DescriptionCohort 1: AUC0-inf of Repaglinide: how it is measured was reworded
  • DescriptionCohort 1: AUC0-t of 1-hydroxymidazolam: how it is measured was reworded
  • DescriptionCohort 1: AUC0-t of Repaglinide: how it is measured was reworded
  • DescriptionCohort 1: Cmax of 1-hydroxymidazolam: how it is measured was reworded
  • DescriptionCohort 1: Cmax of Repaglinide: how it is measured was reworded
  • DescriptionCohort 1: Maximum Observed Plasma Concentration (Cmax) of Midazolam: how it is measured was reworded
  • DescriptionCohort 2: AUC0-inf of Digoxin: how it is measured was reworded
  • DescriptionCohort 2: AUC0-inf of Rosuvastatin: how it is measured was reworded
  • DescriptionCohort 2: AUC0-t of Digoxin: how it is measured was reworded
  • DescriptionCohort 2: AUC0-t of Rosuvastatin: how it is measured was reworded
  • DescriptionCohort 2: Cmax of Digoxin: how it is measured was reworded
  • DescriptionCohort 2: Cmax of Rosuvastatin: how it is measured was reworded
Oct 19, 2026
Documents
Secondary outcomes
1 edited
What changed in the outcomes
  • EditedCohorts 1 and 2: Number of Participant who Experience anParticipants With Treatment-Emergent Adverse EventEvents (TEAEs)Time frame: Up to a maximum 22 days → Cohort 1: Day 1 up to Day 16; Cohort 2: Day 1 up to Day 22
Oct 19, 2026
Show all 1 update
  1. Oct 19, 2026
    Results posted
    Primary outcomes 2 edited, 13 time frame changed, 13 description edited
    What changed in the outcomes
    • EditedCohort 1: Area Under the Plasma Concentration-time Curve (AUC) upFrom Time Zero to Time t, Where t is the Last Point withWith Concentrations Above the Lower Limit of Quantification (AUC0-t) of MidazolamTime frame: Days 1-3 and Days 7-9 → Predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48 hours postdose on Days 1 and 7
    • EditedCohort 1: AUC fromFrom Time 0 to Infinity (AUC0-inf) of MidazolamTime frame: Days 1-3 and Days 7-9 → Predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48 hours postdose on Days 1 and 7
    • Time frameCohort 1: Maximum Observed Plasma Concentration (Cmax) of MidazolamDay 1 and Day 7 → Predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48 hours postdose on Days 1 and 7
    • Time frameCohort 1: Cmax of 1-hydroxymidazolamDay 1 and Day 7 → Predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48 hours postdose on Days 1 and 7
    • Time frameCohort 1: Cmax of RepaglinideDay 1 and Day 7 → Predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24 hours postdose on Days 1 and 7
    • Time frameCohort 2: Cmax of DigoxinDay 1 and Day 8 → Predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 96 hours postdose on Days 1 and 8
    • Time frameCohort 2: Cmax of RosuvastatinDay 1 and Day 8 → Predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 96 hours postdose on Days 1 and 8
    • Time frameCohort 1: AUC0-t of 1-hydroxymidazolamDays 1-3 and Days 7-9 → Predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48 hours postdose on Days 1 and 7
    • Time frameCohort 1: AUC0-t of RepaglinideDays 1-3 and Days 7-9 → Predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24 hours postdose on Days 1 and 7
    • Time frameCohort 2: AUC0-t of DigoxinDays 1-5 and Days 8-12 → Predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 96 hours postdose on Days 1 and 8
    • Time frameCohort 2: AUC0-t of RosuvastatinDays 1-5 and Days 8-12 → Predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 96 hours postdose on Days 1 and 8
    • Time frameCohort 1: AUC0-inf of 1-hydroxymidazolamDays 1-3 and Days 7-9 → Predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48 hours postdose on Days 1 and 7
    • Time frameCohort 1: AUC0-inf of RepaglinideDays 1-3 and Days 7-9 → Predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24 hours postdose on Days 1 and 7
    • Time frameCohort 2: AUC0-inf of DigoxinDays 1-5 and Days 8-12 → Predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 96 hours postdose on Days 1 and 8
    • Time frameCohort 2: AUC0-inf of RosuvastatinDays 1-5 and Days 8-12 → Predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 96 hours postdose on Days 1 and 8
    • DescriptionCohort 1: AUC0-inf of 1-hydroxymidazolam: how it is measured was reworded
    • DescriptionCohort 1: AUC0-inf of Repaglinide: how it is measured was reworded
    • DescriptionCohort 1: AUC0-t of 1-hydroxymidazolam: how it is measured was reworded
    • DescriptionCohort 1: AUC0-t of Repaglinide: how it is measured was reworded
    • DescriptionCohort 1: Cmax of 1-hydroxymidazolam: how it is measured was reworded
    • DescriptionCohort 1: Cmax of Repaglinide: how it is measured was reworded
    • DescriptionCohort 1: Maximum Observed Plasma Concentration (Cmax) of Midazolam: how it is measured was reworded
    • DescriptionCohort 2: AUC0-inf of Digoxin: how it is measured was reworded
    • DescriptionCohort 2: AUC0-inf of Rosuvastatin: how it is measured was reworded
    • DescriptionCohort 2: AUC0-t of Digoxin: how it is measured was reworded
    • DescriptionCohort 2: AUC0-t of Rosuvastatin: how it is measured was reworded
    • DescriptionCohort 2: Cmax of Digoxin: how it is measured was reworded
    • DescriptionCohort 2: Cmax of Rosuvastatin: how it is measured was reworded
    Secondary outcomes 1 edited
    What changed in the outcomes
    • EditedCohorts 1 and 2: Number of Participant who Experience anParticipants With Treatment-Emergent Adverse EventEvents (TEAEs)Time frame: Up to a maximum 22 days → Cohort 1: Day 1 up to Day 16; Cohort 2: Day 1 up to Day 22
    Interventions Arm changed Cohort 1: DC-806 + Midazolam (CYP3A4 substrate) + Repaglinide (CYP2C8 substrate)→Cohort 1: DC-806 / Midazolam (CYP3A4 Substrate) + Repaglinide (CYP2C8 Substrate); Cohort 2: DC-806 + Digoxin (P-gp substrate) + Rosuvastatin (BCRP/OATP1B1 substrate)→Cohort 2: DC-806 / Digoxin (P-gp Substrate) + Rosuvastatin (BCRP/OATP1B1 Substrate)
    + 3 other changes: identifiers, verification date and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT06092931
Responsible party
Sponsor
First posted
Oct 23, 2023
Start date
Oct 16, 2023
Primary completion
Nov 28, 2023
Completion
Nov 28, 2023
Results posted
Oct 19, 2026
Last update
Oct 19, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: DC-806

Start the discussion